Astellas Licenses RIKEN’s aAVC Cell Therapy Technology for US$9.4 M Upfront
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 9 (Table of Contents)
Published: 6 Sep-2019
DOI: 10.3833/pdr.v2019.i9.2455 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Less than a year after it acquired Potenza Therapeutics to break into the immuno-oncology market, Astellas Pharma has now licensed the global rights to RIKEN’s artificial adjuvant vector cell (aAVC) technology for selected cancer antigen targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS